Trial Profile
A single dose,four way,crossover,open label to evalauate the bioavailability of novel formulation of Abiraterone acetate versus the originator Abiraterone acetate formulation in under fasted conditions in healthy male subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Study 101
- 25 May 2017 Results published in the clinical pharmacokinetics journal.
- 03 Apr 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium